Briefly elaborate How preformulation studies help to find the drug performance and the development of a dosage form-Briefly explain this with different drug properties and example?

Which agents associated with cumulative doses resulting in delayed myelotoxicity A Carmustine B Oxaliplatin C fosfamide D Methotrexate NEED DETAILED AND STEP BY STEP ANSWER WITH CORRECT OPTION

Discuss three types of drug-drug interactions, and explain the links to pharmacodynamics and/or pharmacokinetics, with examples.  Give the mechanims.

Briefly explain this statement "Preformulation studies help to find the drug performance and the development of a dosage form"-explain this with different drug properties and example? Please answer at your own easy words.

What are the advantages of inhalation drug delivery systems over other routes of drug administration ? Please briefly explain at your own words.

Discuss why the increase of time intervals decreases the reaction time for analgesic drug.

Please write the Respective Structure Activity Relationship(SAR) of Sedative-hypnotic drugs? Please write at your own words.

Outline the general steps from initial drug discovery to IND filing. Add as much detail as you need and feel free to use flow charts, graphics, visuals, as long as is made by you alone and not directly copied-pasted from another source. If an IND is cleared to proceed by the US-FDA, what is the single most important goal of a first-in-human (FIH) clinical trial?

Give more detail answer Please. Thank You Your current LIS system will no longer be supported by the company, and you have to select a new system. In order to choose the best system for your laboratory. (Keep in mind that you have to continue to provide testing on the current system during this transition.) How will you facilitate the transition from the current system to the new one?

A 70-year-old female patient with Parkinson’s disease has been taking carbidopa/levodopa for five years. Twelve months ago, her physician changed the dose to 8 orally disintegrating tablets (25/100 mg) per day and her symptoms were well-managed until recently. For the last a few weeks, the patient has been experiencing tremors in the hands and slowness in movement towards the end of the dosing interval. Identify the problem and suggest a pharmacotherapy management option for this patient.A 55-year-old male patient has mild dementia and mild hepatic impairment. The patient was recently diagnosed with Parkinson’s disease. Consider carbidopa/levodopa, tolcapone, and rasagiline to initiate treatment.Explain pharmacotherapy of migraine targeting the calcitonin gene-related peptide. Please answer at your own easy words. Answer should be to the point specific. I will rate you positive if you do so. Please don't use AI for answering this question.